# MAGEB5

## Overview
MAGEB5 is a gene that encodes the protein MAGE family member B5, which belongs to the melanoma-associated antigen (MAGE) family. This family of proteins is characterized by their expression in various tumors and restricted presence in normal tissues, primarily the testis. MAGEB5 is implicated in oncogenic processes due to its expression patterns and potential role in cancer progression. The protein encoded by MAGEB5 is not classified as a kinase, receptor, or transmembrane protein, but it is recognized for its involvement in cancer-testis antigen pathways, making it a potential target for cancer immunotherapy (Lucas2000MAGEB5; Achinko2021Targeted).

## Clinical Significance
MAGEB5, a member of the melanoma-associated antigen family, is primarily expressed in tumors and not in normal tissues, except for the testis. Its expression is linked to the demethylation of promoter regions, which is a common feature in various cancers. MAGEB5 has been identified in a seminoma, a malignant neoplasm of the testes, suggesting its potential role in testicular cancer (Lucas2000MAGEB5). The gene's expression in tumors, such as triple-negative breast cancer, indicates its involvement in cancer progression and highlights its potential as a target for therapeutic interventions (Achinko2021Targeted).

The co-expression and co-evolution of MAGEB5 with HHLA2 in certain cancers suggest a functional association that may contribute to oncogenic processes. This relationship is particularly noted in virus-related tumors, where MAGEB5 and HHLA2 are proposed as markers and potential therapeutic targets (Achinko2021Targeted). Despite its limited expression in most tumor types, the presence of MAGEB5 in specific cancers underscores its clinical significance as a cancer-testis antigen, making it a candidate for targeted immunotherapy (Lucas2000MAGEB5).


## References


[1. (Lucas2000MAGEB5) Sophie Lucas, Etienne De Plaen, and Thierry Boon. Mage-b5, mage-b6, mage-c2, andmage-c3: four new members of themage family with tumor-specific expression. International Journal of Cancer, 87(1):55â€“60, 2000. URL: http://dx.doi.org/10.1002/1097-0215(20000701)87:1<55::aid-ijc8>3.0.co;2-j, doi:10.1002/1097-0215(20000701)87:1<55::aid-ijc8>3.0.co;2-j. This article has 91 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/1097-0215(20000701)87:1)

[2. (Achinko2021Targeted) Daniel A. Achinko, Anton Dormer, Mahesh Narayanan, and Elton F. Norman. Targeted immune epitope prediction to hhla2 and mageb5 protein variants as therapeutic approach to related viral diseases. BMC Immunology, July 2021. URL: http://dx.doi.org/10.1186/s12865-021-00440-w, doi:10.1186/s12865-021-00440-w. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12865-021-00440-w)